Novavax (NASDAQ:NVAX) is a leading player in the field of recombinant vaccines. Using its proprietary technology platform, the company is developing vaccines comprising of protein nanoparticles capable of inducing a strong immune response from patients.
Based on impending result from Phase 3 trial, Prepare, believe that Novavax can prove to be a solid investment opportunity in 2017.
RSV F Vaccine for infants via maternal immunization is a robust short-term growth driver for Novavax
David S. Brown Enterprises has bolstered its Retail Leasing team with the recent hiring of Michael Gosnell
The Virginia law firm Gentry Locke is pleased to announce the promotion of Scott A. Stephenson to
Pessin Katz Law is pleased to announce that Attorney Adam E. Konstas has been elected to Member
Skanska, a leading global construction and development firm, announces that Gary Orton has joined the company as
For partnerships, content marketing or advertising inquiries, please contact Edwin through his LinkedIn Profile
Connect© Copyright 2024 citybuzz
